Discover the PCG Difference!
Excellence in Synergy
VIP Glögg mingle: Excellence in Synergy
On November 30th, we joined our collaborators, Antaros Medical and Clinical Trial Consultants (CTC), and many of our partners in celebrating another successful year during our VIP Glögg Mingle at the Uppsala Castle. This atmospheric evening included brief presentations from the three host companies about the unique benefits of our collaboration. Andy Babington, CEO of PCG, introduced the partnership and its basis on ‘one shared passion’, where the three companies are working together to help improve clinical trials. This Uppsala-based initiative brings the full spectrum of services to drug developers in a seamless process, from pre-clinical research through phases I-IV. It combines PCG’s complete CRO services, global reach and expertise with Antaros Medical’s innovative medical imaging capabilities and CTC’s early phase clinical research services.
Per Hagmar, SVP Oncology & Business Development at Antaros Medical, presented the advantages of the company’s combined PET & MRI imaging techniques for visualising drug distribution and efficacy during trials. The approach provides valuable information about a drug’s behaviour and disease biology at early trial stages. This can help to inform decisions on whether to proceed with a candidate therapeutic at much earlier trial stages, potentially saving millions of dollars as well as considerable time and resource that might be wasted on failed drugs.
Tina Nordén, Business Area Manager at CTC, explained CTC’s breadth of services for hospital- and non-hospital-based early phase (from 0-IIa) clinical trials. CTC’s research facilities include a 12-bed phase I research unit that’s conveniently located at Uppsala’s Adakemiska Sjukhuset. The company provides a wide range of study types, from microdose and bioequivalence to drug-drug interactions, medical device and functional food studies. These are supported with many different specialist imaging and analysis techniques, bringing vital additional capabilities to the collaboration with PCG and Antaros.
We were delighted that so many people were able to join the event. The evening provided plenty of opportunity for our guests to meet with leaders from across the clinical development industry. Our achievements this year would not have been possible without our local and global partners, and we look forward to continued success with all of you during 2017.